Ryan Livingston

These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.

A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Stay up-to-date with the latest in FDA decisions, trial readouts, and key clinician insights from all corners of endocrinology.

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.

Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

A new study has indicated the correlation between EHT and atrial myopathy, which in turn contributes to potential ischemic stroke incidence.

The updated ESC guidelines make sweeping changes to HF terminology, eliminating HFmrEF and recategorizing acute HF for patients with slower symptom development.